Study to Evaluate Tezepelumab on Airway Inflammation in Adults With Uncontrolled Asthma (CASCADE)

PHASE2CompletedINTERVENTIONAL
Enrollment

116

Participants

Timeline

Start Date

November 2, 2018

Primary Completion Date

November 16, 2020

Study Completion Date

November 16, 2020

Conditions
AsthmaBronchial DiseasesRespiratory Tract DiseasesLung Diseases, ObstructiveLung DiseasesRespiratory HypersensitivityHypersensitivity, ImmediateHypersensitivityImmune System Diseases
Interventions
BIOLOGICAL

Tezepelumab

Tezepelumab subcutaneous injection

OTHER

Placebo

Placebo subcutaneous injection

Trial Locations (28)

2400

Research Site, København NV

2650

Research Site, Hvidovre

4700

Research Site, Næstved

5000

Research Site, Odense C

7100

Research Site, Vejle

8200

Research Site, Aarhus N

9000

Research Site, Aalborg

15213

Research Site, Pittsburgh

22927

Research Site, Großhansdorf

60389

Research Site, Frankfurt am Main

60596

Research Site, Frankfurt

77555

Research Site, Galveston

80206

Research Site, Denver

86899

Research Site, Landsberg

06510

Research Site, New Haven

02115

Research Site, Boston

T2N 4Z6

Research Site, Calgary

V5Z 1M9

Research Site, Vancouver

L8N 3Z5

Research Site, Hamilton

K1H 8L6

Research Site, Ottawa

H4A 3J1

Research Site, Montreal

G1V 4G5

Research Site, Québec

CB2 0QQ

Research Site, Cambridge

OX3 9DU

Research Site, Headington

LE3 9QP

Research Site, Leicester

W1G 8HU

Research Site, London

NG5 1PB

Research Site, Nottingham

M23 9QZ

Research Site, Wythenshawe

Sponsors

Lead Sponsor

Collaborators (1)

All Listed Sponsors
collaborator

Amgen

INDUSTRY

lead

AstraZeneca

INDUSTRY